CLASSICAL AND ATYPICAL NEUROLEPTICS, AND BONE MINERAL DENSITY, IN PATIENTS WITH SCHIZOPHRENIA
Abstract
There are some reports that classical neuroleptics may lead to osteoporosis or reduced bone mineral density (BMD). However, there is no adequate information about the effects of atypical neuroleptics on BMD. The aim of this study was to measure BMD in schizophrenic patients taking classical and atypical neuroleptics, compared to healthy controls. Seventy-five patients with schizophrenia (40 taking classical neuroleptics [CN], 35 taking atypical neuroleptics [AN]) and 20 healthy controls (HC) were included in the study. Spine (L1-L4) BMD was measured by dual-energy X-ray absorptiometry. ANOVA showed that BMD was higher in HC than AN and CN. In addition, there was a negative correlation between the duration of neuroleptic treatment and BMD and the duration of the illness. These findings suggest that atypical neuroleptics may be safer than the classical neuroleptics in terms of reduced BMD.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
Some studies found a relationship between the use of prolactin-raising medication and low bone mineral density in patients with chronic schizophrenia, while others failed to find a relationship between prolactin, antipsychotics and osteoporosis.
“Some studies (490-493) found a relationship between the use of prolactin-raising medication and low BMD in patients with chronic schizophrenia, while others (474,489,494-498) failed to find a relationship between prolactin, AP and osteoporosis.”
From Physical illness in patients with severe mental disorders. I. Prevalence, impact of medications and disparities in health care (2011) · cites this paper as [493]
The citation lists haven’t been fetched yet
References 38 · Cited by 48
- Authors
- BILICI, M., CAKIRBAY, H., GULER, M., TOSUN, M., ULGEN, M., & TAN, U.
- Venue
- International Journal of Neuroscience
- Publisher
- Informa UK Limited
- Published
- 2002-01
- Volume
- 112
- Issue
- 7
- Pages
- 817-828
- ISSN
- 0020-7454 (ISSN-L)
- 1543-5245
- OpenAlex
- W2018442412
- Cited by
- 48
- References
- 38
- Citations by year
- 2024: 1 · 2021: 1 · 2017: 1 · 2016: 2 · 2015: 3 · 2014: 1 · 2013: 4 · 2012: 4
- FWCI
- 1.49
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- International Journal of Neuroscience (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Psychiatry and Mental health › Schizophrenia research and treatment
- Health Sciences › Medicine › Orthopedics and Sports Medicine › Bone health and osteoporosis research
- Health Sciences › Medicine › Pediatrics, Perinatology and Child Health › Pharmacological Effects and Toxicity Studies
- Keywords
- schizophrenia, bone mineral density, atypical antipsychotics, osteoporosis, antipsychotic adverse effects, spine, disease duration
- MeSH terms
- Olanzapine, Adult, Analysis of Variance, Benzodiazepines, Clopenthixol, Clozapine, Female, Fluphenazine, Haloperidol, Humans, Male, Pirenzepine, Schizophrenia, Antipsychotic Agents, Bone Density, Risperidone
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
